# Abbott

Type: Company (ABT)

Source: GetYourBrief — https://getyourbrief.com/entity/abbott
Canonical HTML page: https://getyourbrief.com/entity/abbott

## Timeline

- **2026-09-01**: Public breach disclosure — Novocure publicly reported the cyberattack, disclosing that internal records of more than 1,400 U.S. patients were exposed.
- **2026-08**: Unauthorized access occurs — Novocure says unauthorized access to certain information systems occurred in mid-August 2026, exposing internal patient records.
- **2026-08**: Incident response activated — Novocure activated its cybersecurity response plan, implemented containment measures, and initiated an internal investigation.

## Recent coverage (3 stories, network-wide)

### Novocure cyberattack exposes 1,400+ US patient records
2026-09-02 00:10:45 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 2

Novocure disclosed a mid-August cyberattack that exposed internal records of more than 1,400 U.S. oncology patients, along with provider contact details and employee job titles. The company said treatment devices were not accessed and that it expects no material financial impact. For healthcare IT and compliance leaders, the incident is another compelling case study in breach response, data classification, and regulatory risk.
Full story: https://gethealthbrief.com/story/novocure-cyberattack-1400-patient-records

### Seveno Capital Backs PointFit to Disrupt Wearables with Sweat-Sensing Tech
2026-03-09 07:34:43 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Seveno Capital has announced a strategic investment in PointFit, a biotech startup developing a non-invasive sweat-sensing skin patch. The partnership aims to transition the wearable market from mechanical tracking to real-time biochemical analysis using proprietary nanomembrane technology.
Full story: https://getbiobrief.com/story/seveno-capital-pointfit-investment-wearable-biotech

### GLP-1 Nutrition: The Next Frontier in Metabolic Health Management
2026-02-19 10:41:13 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 7

As GLP-1 receptor agonists like semaglutide and tirzepatide dominate the obesity market, the focus is shifting toward integrated nutritional strategies to mitigate muscle loss and gastrointestinal side effects. This evolution marks a transition from simple weight reduction to comprehensive body composition management.
Full story: https://getbiobrief.com/story/glp-1-nutrition-metabolic-health-management

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.